Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

39.41
+0.04000.10%
Post-market: 39.410.00000.00%19:34 EDT
Volume:727.08K
Turnover:28.62M
Market Cap:8.09B
PE:-14.22
High:39.87
Open:39.80
Low:38.70
Close:39.37
52wk High:41.23
52wk Low:14.32
Shares:205.31M
Float Shares:79.83M
Volume Ratio:0.82
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7716
EPS(LYR):-2.7716
ROE:-64.82%
ROA:-38.43%
PB:9.49
PE(LYR):-14.22

Loading ...

Company Profile

Company Name:
Immunovant, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
315
Office Location:
1000 Park Forty Plaza,Suite 210,Durham,North Carolina,United States
Zip Code:
27713
Fax:
- -
Introduction:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Directors

Name
Position
Eric Venker
Chief Executive Officer and Director
Andrew Fromkin
Independent Director
Atul Pande
Independent Director
Douglas Hughes
Independent Director
Frank M. Torti
Director and Executive Chairperson of the Board
Jacob Bauer
Independent Director
Robert Susman
Independent Director

Shareholders

Name
Position
Eric Venker
Chief Executive Officer and Director
Melanie Gloria
Chief Operating Officer
Tiago Girão
Chief Financial Officer
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Frank M. Torti
Director and Executive Chairperson of the Board
Jay S. Stout
Chief Technology Officer